


PHARMACEUTICAL 2021

Kindred Biosciences Inc. Rank 130 of 409







Kindred Biosciences Inc. Rank 130 of 409

The relative strengths and weaknesses of Kindred Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kindred Biosciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 206% points. The greatest weakness of Kindred Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is -23%, being 332% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	62,624
Cost of Goods Sold	4,626
Intangible Assets	0
Liabilities, Current	6,896
Liabilities, Non-Current	2,934
Other Assets	4,986
Other Compr. Net Income	-1.0
Other Expenses	4,246
Other Liabilities	18,502
Other Net Income	-1,828
Property and Equipment	28,204
Research and Development	31,281
Revenues	42,164
Selling, General and Administrative Expense	21,979

Output Variable	Value in 1000 USD
Assets	95,814
Liabilities	28,332
Expenses	62,132
Stockholders Equity	67,482
Net Income	-21,796
Comprehensive Net Income	-21,796
Economic Capital Ratio	-23%

